Scientists at the University of Cambridge have created a test that could predict if a cancer patient is sensitive or ...

CNS Pharmaceuticals (NASDAQ: CNSP) announced the release of a Virtual Investor KOL Connect segment featuring Dr. Erin Dunbar, Director of Neuro-Oncol ...

Cancer Research UK-funded scientists at the University of Cambridge create a test to predict resistance to chemotherapy. The test uses changes to cancer DNA at diagnosis to predict which patients will ...

Tens of thousands of cancer patients going through gruelling chemotherapy could have DNA test to predict which form of the ...

Race Oncology Ltd. ( ($AU:RAC) ) has issued an announcement. Race Oncology announced the successful and safe dosing of the first patient with a ...

Watch the “What This Means" segment here HOUSTON, June 18, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ( ...

Detailed price information for Moleculin Biotech CS (MBRX-Q) from The Globe and Mail including charting and trades.

Despite an initial complete remission of 60%-80% in patients receiving anthracycline/cytarabine induction, acute myeloid leukemia (AML) shows a suboptimal long-term outcome rate. Serine/threonine ...

Oncologists vary widely in treating DLBCL with cardiomyopathy, often diverging from guidelines due to limited evidence on ...

VANFLYTA (quizartinib) has been approved by Health Canada for use in combination with standard cytarabine and anthracycline ...

The most common types of cancer were lymphoma (40.2%) and breast cancer (32.4%), 36.1% had metastatic disease, 93.5% received doxorubicin, and the average cumulative anthracycline dose was 198.1± ...